vTv Therapeutics Inc (VTVT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $31.07 (-1.05%), Market cap $0.14B, 52-week low–high $14.00 ~ $42.72.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point,
Financial statements, price targets, institutional (13F) holdings and related news for vTv Therapeutics Inc are updated in real time on BlackAll Trade.
vTv Therapeutics Inc trades at $31.07 (-1.05%). Real-time quotes and charts are available on BlackAll Trade.
vTv Therapeutics Inc has a market cap of about $0.14B.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its l